Sophie McGrath is a partner in Goodwin’s Technology and Life Sciences groups. Ms. McGrath focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams. She advises on a wide range of corporate matters, including private and public financings, mergers and acquisitions, public offerings and restructurings.

Ms. McGrath is a recommended lawyer for Chambers UK and Legal 500. She is described by Legal 500 as “one of the best VC lawyers in the market. She has unbeatable knowledge and experience, especially in the life sciences and technology industries” and by Chambers as applying a “very commercial” approach to deals in the life sciences and technology sectors. 

Ms. McGrath also has a keen interest in the impact investment sector, acting for both investors and companies that are targeting a “double bottom line,” either through environmental or social impact, and is a member of the British Venture Capital Association’s Impact Investment advisory group, which has a mandate to promote the development of the impact investment sector in the UK.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Representative Matters

REFERENZMANDATE

代表事项

Life Sciences & Healthcare
  • Morningside Ventures on its lead investment of a $50,000,000 Series B funding round into Ieso Digital Health Limited, who deliver high-quality, online cognitive behavioural therapy to NHS patients.
  • Jefferies LLC on their at the market sales transaction for up to $100,000,000 American Depositary Shares with Silence Therapeutics plc (AIM:SLN and Nasdaq: SLN), a biotech company developing gene therapeutic technology based on RNA interference.
  • Kinnevik on their Series C $100 million investment into Spring Health, a leading global mental health solution.
  • COMPASS Pathways plc on its public follow-on offering on NASDAQ of American Depositary Shares for gross proceeds of approximately $144 million.
  • COMPASS Pathways plc on its completed upsized $146.6 million NASDAQ initial public offering.
  • Omega Funds on co-leading Artios Pharma Limited’s $153 million Series C financing.
  • Achilles Therapeutics plc on its Initial Public Offering on NASDAQ with total proceeds of $175.5 million. Achilles is a biopharmaceutical company developing personalised cancer immunotherapies.
  • Kinnevik on their Series B $64m funding round in Quit Genius, the world’s first digital clinic for treating nicotine, alcohol and opioid addictions.
  • Jeito Capital on leading an oversubscribed $92 million Series C financing round in Artios Pharma Limited, a DNA Damage Response company with a strong pipeline of novel cancer therapies in development.
  • Thymia, an online platform which removes subjectivity from mental health assessments, on its series seed funding round.
  • Quanta Dialysis Technologies on multiple private funding rounds including its most recent $245 million oversubscribed Series D funding round, the largest private funding round for a dialysis device company in history.
  • Lauxera Capital Partners on their investment in LUMICKS, a supplier of Dynamic Single-Molecule and Cell Avidity analysis instruments, as part of a $93 million Series D Financing.
  • Arix Bioscience Holdings Limited, a global venture capital company focused on investing in and building breakthrough biotech companies, on the completion of its €1.5 million investment into Twelve Bio ApS as part of its €4 million seed round.
  • Morningside Ventures, and early stage venture investor, on the completion of its £23.7 million investment into Immune Regulation Limited as part of a £40.6 million Series B funding round.
  • Novo Holdings A/S, a leading international life sciences investor, on its $40 million investment as part of a $60 million Series C funding round into Exscientia Limited, a world leading AI-driven drug discovery company based in the UK.
  • Coöperatieve Gilde Healthcare IV U.A., a specialised European healthcare-focused investment fund based in the Netherlands, on its $10 million investment in Big Health Ltd as part of a $25 million Series B.Big Health’s purpose is to help millions back to good mental health, with digital therapeutics - fully automated and highly personalised behavioural programs for mental health.
  • Advanced Medical Solutions Group plc, an AIM listed life sciences company, on its acquisition of Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform.
Technology Experience
  • Wintermute, a leading global crypto market maker, on their $20 million Series B funding round.
  • Kinnevik on their investment into Sure, Inc, an insurtech company.
  • Sprout.ai Limited, an insurtech company providing AI to support claims and fraud teams, on its £8 million Series A funding round led by Octopus Ventures.
  • DST Global and General Catalyst on a $150 million Series C Financing of Zego, a London, UK-based motor insurtech company, giving it a $1.1 billion valuation and unicorn status.
  • Brytlyt Limited, a company that is developing and commercializing GPU-accelerated data processing technology, on its completion of a £3.2 million Series A funding round led by Amadeus V Technology Fund LP and Finch Capital Fund II Cooperatief U.A.
  • Joanna Dai Limited, a luxury performance workwear brand specializing in sustainable, versatile and high-tech women’s workwear, on its seed funding round.
  • Cognitive Credit, a company developing an end-to-end analytics application that delivers cutting edge technology to institutional credit investors, on multiple private financing rounds including its series A funding round.
  • Beyond.Life Ltd, providing an online marketplace that connects funeral directors and at-need customers, on its Series A round.
  • Novastar Ventures Limited, an impact investment fund, on its Series A investment in The Sure Chill Company Limited, a company that develops a revolutionary platform cooling technology.
Professional Activities

Ms. McGrath is a member of the British Venture Capital Association.

Ms. McGrath is an Expert in Residence for Women of Wearables.

Recognition

  • Ms. McGrath was recognized by Chambers UK 2022 for her work in Private Equity: Venture Capital Investment.
  • Ms. McGrath has been shortlisted for Legal Adviser of the Year by the Women in Finance Summit & Awards Series 2021.
  • Ms. McGrath has been recognised as a leading individual by Legal 500 UK 2022 for Venture Capital where she is described as “one of the best VC lawyers in the market. She has unbeatable knowledge and experience, especially in the life sciences and technology industries.”
  • Ms. McGrath was recognized by Chambers 2021 UK for her work in Private Equity: Venture Capital Investment.
  • Ms. McGrath has extensive experience in private investment work, acting for companies at all stages of development, as well as investors and management teams. She is a recommended lawyer in Chambers UK 2020 in the field ‘Private Equity: Venture Capital Investment.’

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

Qualified Lawyers Transfer Test, 2003
College of Law London
Graduate Diploma in Law, 1999
College of Law, Sydney
Bachelors in Commerce and Laws, 1998
University of Sydney

Admissions

Bar

Solicitor of the Senior Courts of England and Wales
New South Wales, Australia
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师